1. Pink Sheet

In Brief

Hi-Tech absorbs hit from Sandy; Meda strikes MidNite deal; Sunscreen labeling due date nears; ChromaDex picks up Spherix Consulting; Chemi Pharmaceutical allegedly falsified tests; Actavis exec Boothe joins Perrigo.

The Amityville, N.Y., facilities of Hi-Tech Pharmacal Co. Inc. lost power from Oct. 29 to Nov. 1 due to Hurricane Sandy and did not produce or ship any Rx or OTC products during that stretch. Though its facilities were not damaged, Hi-Tech lost four days of sales opportunities for cough/cold/flu OTCs while retail orders for those products surged, CEO David Seltzer said Dec. 6. Employees are working overtime now to catch up and the firm expects to make up the lost sales during its current fiscal third quarter, which ends in January. For the preceding quarter ended Oct. 31, Hi-Tech reported net sales up 1.2% to $57.5 million while net income declined 35.3% to $8.9 million as research and development costs jumped 35.5% to $3.3 million. Hi-Tech’s OTC health care products division recorded second-quarter sales essentially flat at $4.7 million, as discounting for the Nasal Ease brand offset sales of the Sinus Buster product acquired in March.

Meda AB expands its consumer health portfolio with the addition of the MidNite herbal sleep support supplement line in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

More from Pink Sheet

EU CHMP Opinions And MAA Updates

 
• By Neena Brizmohun

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

Crosstalk On Drug Pricing: Conflicts In Trump Team Rhetoric And Policy

 
• By Michael McCaughan

The Trump Administration’s rhetoric and policy approaches illustrate the confusion that often arises between efforts to cut drug prices and cutting spending.

Price Inflation Rebates: Biden Policies Add Teeth To Trump’s Pharma Tariff Threat

 
• By Cathy Kelly

Companies with significant exposure to Medicare and Medicaid have fewer options for passing along higher costs to consumers because of price controls in the programs.